CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
estrogen replacement therapy +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000559
NCT00000559Phase 3Completed
CompareCT.gov

Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Jul 12, 2016

In Brief

A Phase 3 clinical trial evaluating estrogen replacement therapy, hormone replacement therapy, and 2 other interventions for Cardiovascular Diseases and 4 related conditions. Completed.

Detailed Summary

To determine the effects, in postmenopausal women, of hormone replacement therapy on progression/regression of coronary heart disease, as measured by quantitative angiography.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Ischemia, Postmenopause
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartMar 1, 1995
Study CompletionAug 1, 2001
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

estrogen replacement therapydrug

hormone replacement therapydrug

estradioldrug

medroxyprogesteronedrug